Effectiveness of Spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (The Randomized Aldactone Evaluation Study [RALES])

American Journal of Cardiology

Volumn 78, Issue 8, 1996, Pages 902-907

  Pitt, Bertram ^a  

^a UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; DIGITALIS GLYCOSIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; SPIRONOLACTONE;

ADULT; AGED; ARTICLE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; FEMALE; HUMAN; HYPERKALEMIA; MALE; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; AGED, 80 AND OVER; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIGITALIS GLYCOSIDES; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FUROSEMIDE; HEART FAILURE, CONGESTIVE; HUMANS; HYPERKALEMIA; MALE; MIDDLE AGED; SPIRONOLACTONE;

EID: 0030587794     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(96)00465-1     Document Type: Article

References (25)

1. Hall JE, Brands MW. Intrarenal and circulating angiotensin II and renal function. In: Robertson JIS, Nicholls MG, eds. The Renin-Angiotensin System. London: Gower Medical, 1993.
2. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation 1991;83:1849-1865.
3. Weber KT, Villarreal D. Aldosterone and antialdosterone therapy in congestive heart failure. Am J Cardiol 1993;71:3A-11A.
4. Barr CS, Lang CC, Hanson J, Arnott M, Kennedy N, Struthers AD. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995;76:1259-1265.
5. Staessen J, Lijnen P, Fagard R, Verschueren LJ, Amery A. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 1981;91:457-465.
6. Marayev V, Skvortsov A, Masenko V, Belenkov Y. Escape of ACE inhibitor effects on aldosterone during long-term treatment of congestive heart failure. Presented at the International Meeting on Heart Failure, Amsterdam, April 1995. Abstract.
7. Aldigier JC, Huang H, Dalmay F, Lartigue M, Baussant T, Chassain AP, Levoux-Robert C, Galen FX. Angiotensin-converting enzyme inhibition does not suppress plasma angiotensin II increase during exercise in humans. J Cardiovasc Pharmacol 1993;21:289-295.
8. Borghi C, Boschi S, Ambrosioni E, Melandri G, Branzi A, Magnani B. Evidence of a partial escape of renin-angiotensin-aldosterone blockage in patients with acute myocardial infarction treated with ACE inhibitors. J Clin Pharmacol 1993;33:40-45.
9. Rousseau MF, Konstam MA, Benedict CR, Donckier J, Galanti L, Melin J, Kinan D, Ahn S, Ketelslegers, JM, Pouleur H. Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor. Am J Cardiol 1994;73:488-493.
10. Urata H, Healy BH, Stewart R, Bumpus FM, Husain A. Angiotensin II forming pathways in normal and failing human hearts. Circ Res 1990;66:883-890.
11. Muller J. Spironolactone in the management of congestive cardiac failure: a review. Clin Ther 1986;9:63-76.
12. Ikram H, Lewis GRJ, Webster MWI, Richards AM, Nicholls MG, Crozier IG. Combined spironolactone and converting-enzyme inhibitor therapy for refractory heart failure. Aust NZ J Med 1986;16:61-63.
13. van Vliet AA, Donker AJM, Nauta JJP, Verheugt FW. Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin converting enzyme inhibitor. Am J Cardiol 1993;71:21A-28A.
14. Han Y-L, Tong M, Jing Q-M, Hu X-L, Liu J-Q. Combined therapy of captopril and spironolactone for refractory congestive heart failure. Chin Med J 1994;107:688-692.
15. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L, for the CONSENSUS Trial Study Group. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 1990;82:1730-1736.
16. Cody RJ. The need for a sodium retention score in clinical trials of heart failure. Clin Pharmacol Ther 1993;54:7-10.
17. Haug C, Metzele A, Kochs M, Hombach V, Grunert A. Plasma brain natriuretic peptide and atrial natriuretic peptide concentrations correlate with left ventricular end-diastolic pressure. Clin Cardiol 1993;16:553-557.
18. Pfeffer MA, Braunwald E, Moye LA, on behalf of the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992;327:669-677.
19. Konstam M, Dracup K, Baker DW, Bottorff MB, Brooks NH, Dacey RA, Dunbar SB, Jackson AB, Jessup M, Johnson JC, Jones RH, Luchi RJ, Massie BM, Pitt B, Rose E, Rubin LJ, Wright RF, Hadorn DC. Heart Failure: Evaluation and Care of Patients with Left-Ventricular Systolic Dysfunction. Clinical Practice Guideline No. 11. AHCPR Publication No. 94-0612. Rockville, MD: Agency for Health Care Policy and Research. Public Health Service, U.S. Department of Health and Human Services. June 1994.
20. Francis GS, Cohn JN, Johnson G, Reetor TS, Goldman A, for the V-HeFT VA cooperative studies group. Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. Circulation 1993;87(suppl VI):VI-40-VI-48.
21. Leier CV, Livio DC, Metra M. Clinical relevance and management of the major electrolyte abnormalities in congestive heart failure: hyponatremia, hypokalemia, and hypomagnesemia. Am Heart J 1994;128:564-574.
22. Cleland JGF, Dargie HJ, Robertson I, Robertson JIS, East BW. Total body electrolyte composition in patients with heart failure: a comparison with normal subjects and patients with untreated hypertension. Br Heart J 1987;58:230-238.
23. Packer M, Lee WH, Yushak M, Medina N. Comparison of captopril and enalapril in patients with severe chronic heart failure. N Engl J Med 1986;315:847-852.
24. Physician Drug and Diagnosis Audit, Scott-Levin Associates, Newtown, PA, 1994.
25. Physicians' Desk Reference. 50th ed. Montvale, NJ: Medical Economics Company; 1996:2414-2416.